Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
Authors
Armstrong, A. J.Saad, F.
Thiery-Vuillemin, A.
Oya, M.
Shore, N. D.
Mehra, N.
Ozguroglu, M.
Gedye, C.
Sartor, O.
Poehlein, C. H.
Qiu, P.
Liu, Y. Z.
Riva, L.
Harrington, L.
Barker, L.
Del Rosario, P. M. D.
Barnicle, A.
Clarke, Noel W
Affiliation
Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NCIssue Date
2022
Metadata
Show full item recordCitation
Armstrong AJ, Saad F, Thiery-Vuillemin A, Oya M, Shore ND, Mehra N, et al. Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Annals of Oncology. 2022 Sep;33(7):S1168-S. PubMed PMID: WOS:000866211601627.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1502Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1502Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1502